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A randomised controlled trial to evaluate the
efficacy of a 6 month dietary and physical activity
intervention for prostate cancer patients
receiving androgen deprivation therapy
Farhana Haseen1*, Liam J Murray1, Roisin F O’Neill1, Joe M O’Sullivan2, Marie M Cantwell1
Abstract
Background: Treatment with Androgen Deprivation Therapy (ADT) for prostate cancer is associated with changes
in body composition including increased fat and decreased lean mass; increased fatigue, and a reduction in quality
of life. No study to date has evaluated the effect of dietary and physical activity modification on the side-effects
related to ADT. The aim of this study is to evaluate the efficacy of a 6-month dietary and physical activity
intervention for prostate cancer survivors receiving ADT to minimise the changes in body composition, fatigue and
quality of life, typically associated with ADT.
Methods: Men are recruited to this study if their treatment plan is to receive ADT for at least 6 months. Men who
are randomised to the intervention arm receive a home-based tailored intervention to meet the following
guidelines a) ≥ 5 servings vegetables and fruits/day; b) 30%-35% of total energy from fat, and < 10% energy from
saturated fat/day; c) 10% of energy from polyunsaturated fat/day; d) limited consumption of processed meats; e)
25-35 gm of fibre/day; f) alcoholic drinks ≤ 28 units/week; g) limited intake of foods high in salt and/or sugar. They
are also encouraged to include at least 30 minutes of brisk walking, 5 or more days per week. The primary
outcomes are change in body composition, fatigue and quality of life scores. Secondary outcomes include dietary
intake, physical activity and perceived stress. Baseline information collected includes: socio-economic status,
treatment duration, perceived social support and health status, family history of cancer, co-morbidities, medication
and supplement use, barriers to change, and readiness to change their health behaviour. Data for the primary and
secondary outcomes will be collected at baseline, 3 and 6 months from 47 intervention and 47 control patients.
Discussion: The results of this study will provide detailed information on diet and physical activity levels in
prostate cancer patients treated with ADT and will test the feasibility and efficacy of a diet and physical activity
intervention which could provide essential information to develop guidelines for prostate cancer patients to
minimise the side effects related to ADT.
Trial registration: ISRCTN trial number ISCRTN75282423
Background
Prostate cancer is the most common cancer in men in
the United Kingdom, with more than 35,000 new cases
diagnosed each year [1]. The number of prostate cancer
survivors is increasing each year due to advances in can-
cer detection, treatment and care. Recent statistics
(2001-2006) have shown that, in the absence of other
competing causes of death, an estimated 77% of those
diagnosed with prostate cancer can expect to be alive in
5 years, whereas in 1991-1995 the five-year survival rate
was estimated at < 54% [1]. Therefore, as the number of
prostate cancer survivors and their length of survival
increases, health issues specific to prostate cancer survi-
val are fast emerging as a public health concern.
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Treatment of prostate cancer is based on a patient’s
age, co-morbidity, stage and grade of the prostate
tumour and local availability of treatment [2]. Standard
therapies for localised prostate cancer include radical
prostatectomy, external beam radiotherapy, brachyther-
apy, often combined with androgen deprivation therapy
(ADT). For more advanced prostate cancer ADT is a
standard part of the management for the majority of
patients and has been conclusively shown to improve
survival [3]. Because of increasing evidence of the bene-
fit of ADT in prostate cancer, the number of prescrip-
tions of ADT for treating prostate cancer in the UK
increased from 33,000 in 1987 to 470,000 in 2004 [4].
However, treatment with ADT is associated with signifi-
cant adverse physiological and psychological effects. For
example, the reduction in testosterone levels by ADT
causes a decrease in lean body mass and muscle
strength, a reduction in bone mass and bone mineral
density, an increase in fat mass, total body weight and
cholesterol levels; a reduction in haemoglobin levels and
as a result increased lethargy, which can affect both phy-
sical and physiological function [5-7].
A diet and physical activity intervention that could
address some of these side effects could be beneficial to
prostate cancer patients treated with ADT. Experimental
studies examining the role of exercise during ADT treat-
ment for prostate cancer have shown that 10-20 weeks
of exercise is an effective way to reduce fatigue and
depression, improve quality of life, increase muscular fit-
ness and strength [8-11], and improve physical func-
tional capacity preventing adverse effects on body
composition [9]. Indeed 20 weeks of exercise has been
shown to preserve lean body mass and prevent an
increase in fat mass [11]. Changes in dietary intake at
the time of treatment may also help to counteract the
changes in body composition associated with ADT. Sev-
eral randomised controlled trials (RCTs) of diet and
physical activity interventions in prostate cancer patients
have begun in recent years and include the FRESH
START trial, Project LEAD, and RENEW. However the
men recruited within these studies have received all
types of treatment modalities [12-14]. Therefore, the
impact of a diet and physical activity intervention on the
side-effects related to ADT, a group that experiences
major changes in body composition, has not yet been
discussed in any of these studies.
To date very little information is known about dietary
intake and physical activity levels of prostate cancer
patients in the UK. In general however, cancer patients
are highly motivated to seek information about food
choices, physical activity, dietary supplement use, and
complementary nutritional therapies in an attempt to
improve their response to treatment, speed-up recovery
rates, reduce the risk of cancer recurrence, and/or to
improve their quality of life [15]. The American Cancer
Society has recently published nutrition and lifestyle
guidelines for cancer survivors [16] although the impact
of these guidelines on outcomes relevant to prostate
cancer patients treated with ADT are unknown. In addi-
tion, for long-term prostate cancer survivors, an appro-
priate weight, a healthy diet, and a physically active
lifestyle aimed at preventing recurrence, second primary
cancers, and other chronic diseases should be a priority.
Therefore, we have developed an intervention aimed at
encouraging patients treated with ADT to meet healthy
eating guidelines and achieve at least 30 minutes of
brisk walking at least 5 days per week to reduce treat-
ment related side-effects and improve overall quality of
life.
Objectives
Primary objective
The study is intended to evaluate the efficacy of a
6 month dietary and physical activity intervention for
prostate cancer survivors receiving ADT. The outcomes
of interest are body composition, fatigue and quality of
life.
Specific objectives
We will also describe the nutritional status, dietary
intake and physical activity level among prostate cancer
survivors in Northern Ireland. The effect of the inter-
vention on dietary intake, level of physical activity, qual-
ity of life, fatigue, and psychological stress will be
assessed by comparing the intervention group with the
controls. Moreover the stages of readiness to change
lifestyle behaviours in prostate cancer survivors after
diagnosis and during ADT will be measured using the
transtheoretical model.
Hypothesis
We hypothesize that a diet and physical activity inter-
vention will prevent or reduce weight gain, and mini-
mize the increase in body fat mass typically found in
patients treated with ADT in the intervention group
compared with the controls. We also hypothesize that
the intervention patients will experience less fatigue and
will have a better quality of life score compared with the
controls.
Method
Design
Patients are randomised either to receive the dietary
modification and physical activity intervention or stan-
dard care (control group) with a 1:1 allocation ratio
(Figure 1).
Setting and participants
Prostate cancer patients are recruited from the Cancer
Centre at Belfast City Hospital, Belfast, Northern
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Ireland, United Kingdom. Our inclusion and exclusion
criteria are as follows.
Inclusion criteria
1) histologically proven adenocarcinoma of prostate; and
2) commencing Lutenising Hormone Releasing Hor-
mone Agonist (LHRHa) therapy for at least 6 months or
already being treated with LHRHa and planned to con-
tinue for at least a further 6 months
Exclusion criteria
1) co-morbid conditions that limit physical activity such
as severe cardiac disease, recent myocardial infarction,
severe asthma or breathlessness, uncontrolled hyperten-
sion (blood pressure > 160/95 mm/Hg), or severe pain;
2) medical conditions that require a reduced fruit and
vegetable diet (e.g. kidney failure); 3) history of insulin
dependent diabetes; 4) treated with any type of steroid
hormone; 5) treated for any other cancer; and 6) life
expectancy of less than 2 years.
Sample size
This study is an exploratory one and so formal power
calculations are difficult. The primary endpoint used to
calculate sample size was body composition. Smith et al
[17] presented data from a study of prostate cancer
Figure 1 Study Design in flow diagram. Recruitment, randomisation, follow-up and outcomes assessment.
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patients treated with hormone therapy and the mean
percentage change in fat mass following ADT treatment
was 9.4% (SD = 9.6%). If it is assumed that the controls
in the planned study will have a similar percentage of
fat mass, then with 36 patients in the intervention group
and 36 patients in the control group the study will have
90% power at 5% significance to detect a mean percen-
tage change in fat mass of 7.4% between the control and
intervention group. An additional 30% was added to the
sample size calculation to account for non-compliance
and potential drop-out or discontinuation. Therefore 47
patients will be randomised to the intervention and 47
randomised to the control group. This sample size will
also allow us to detect a 3.4 point (SD = 5.0 points) dif-
ference in Fatigue Severity Score [8] (a 3 point differ-
ence on the fatigue scale is considered to be the
minimal clinically important difference) [18]; and a
6.0 point (SD = 9.0 points) difference on the Functional
Assessment of Cancer Therapy-General (FACT-G)
score [8].
Recruitment of patients
Hospital notes are initially checked to identify eligible
patients. The patient’s consultant confirms their eligibil-
ity in terms of clinical conditions related with mobility.
The study objectives, hypotheses, design and data collec-
tion procedures are then discussed with patients who
meet the inclusion criteria. They are given an informa-
tion sheet to read at home and are then phoned within
3-5 days to get their verbal consent to participate in the
study. An appointment date is arranged for collection of
baseline data at the clinic. Prior to the visit, a set of self-
administered questionnaires are mailed to the patient
for completion and they are asked to bring the com-
pleted questionnaires to their next visit. Patients provide
written consent on the day of recruitment; before data
collection. Midterm and final assessment dates are then
scheduled for a 3 month (13 weeks) and 6 month
(25 weeks) follow-up visit (Figure 1).
Randomisation
Patients are randomised using a block randomisation
approach with computer generated random numbers, to
the intervention and control group, with equal probabil-
ity that they are randomised to the intervention or con-
trol arm. Using a block size of four there are six
sequence permutations to which we can allocate
patients to the intervention (I) and control (C) arms:
IICC, ICIC, ICCI, CIIC, CICI, and CCII. One of the six
permutations was selected randomly and then four
patients assigned accordingly. The process was repeated
to allocate patients to the intervention and control arms
for the required sample size. An independent researcher
constructed the allocation sequence and sealed these in
individual opaque envelopes with study identification
numbers on the front. Patients are only numbered once
they have provided verbal consent by phone. Randomi-
sation takes place at an individual level after the baseline
measurements have been taken and approximately one
week prior to the start of the intervention. Therefore,
the researcher does not know the allocation of the
patients until the baseline data collection has been com-
pleted. Similarly patients are consented to the study
before they know which group they will have been allo-
cated to.
Intervention
Those patients randomised to the intervention arm
receive the intervention from a qualified nutritionist.
Within a week after their baseline measurements are
taken, the nutritionist visits the patients at their
home to describe and deliver the intervention which
has two components; dietary modification and physi-
cal activity.
Dietary modification
The dietary advice is developed based on the patients’
usual dietary intake, measured at baseline using a 7-day
food diary. They are provided with individually tailored
advice to encourage them to adopt a diet that is com-
mensurate with current dietary guidelines [19] and, spe-
cifically, to meet the following criteria;
a) Eat 5 or more servings of vegetables and fruits per
day
b) Reduce total fat intake to 30%-35% of total
energy, with < 10% of energy from saturated fat
c) Limit polyunsaturated fat intake to 10% of daily
total energy intake
d) Limit consumption of processed meats
e) Eat fibre-rich foods. Aim to consume 25 to 35 g
of fibre daily
f) Limit alcohol intake ≤ 28 units/week
g) Limit intake of foods high in salt and/or sugar
Moderate physical activity
Brisk walking at least 30 min per day, in addition to
usual activities on 5 or more days of the week.
The diet and physical activity intervention is tailored
to each patient based on the information collected dur-
ing their baseline interview. The nutritionist meets each
patient to discuss their calculated energy and nutrient
requirements. Dietary recommendations are based on
the information collected on weight, physical activity
levels and baseline dietary intake. Energy is calculated
based on actual body weight; however, 500 kcal/day
reduction is advised to the overweight/obese patients to
prevent or reduce weight gain. Each patient in the inter-
vention arm receives an individualised guidebook with
tips and guidelines to help adherence to the diet. The
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guidebook includes; a sample menu to provide an exam-
ple of the amounts and type of foods that can be
included for breakfast, lunch, dinner and snacks; a list
of portion sizes for foods typically eaten; tips to incorpo-
rate more fruit, vegetables and fibre, and reduce total
fat, saturated fat, sugar and salt; a list of healthier foods
choices and a list of foods that should be chosen less
frequently from all food groups; examples of healthy
alternative menus for breakfast, snacks, lunch and
dinner.
The physical activity intervention is also tailored to
each patient based on their baseline physical activity
level. As a minimum, each patient is asked to walk at a
brisk pace for at least 30 minutes per day, 5 times or
more per week. However, men who are already physi-
cally active are advised to increase the duration and fre-
quency of walking each week. They are also asked to set
a goal of increasing the number of steps by at least 10%
every week. A pedometer is provided to each participant
in an effort to encourage them to comply with the phy-
sical activity intervention and as an independent mea-
sure of physical activity levels during the intervention
period.
Men in the control group will receive standard care
during the intervention period but will be offered the
same guidelines at the end of the 6 month intervention.
Data collection
Data to evaluate the efficacy of the intervention are col-
lected at baseline and at 3 and 6 months after the inter-
vention has begun in the intervention and control
group. Data are collected via interview, self admini-
strated questionnaire, physical and biological measure-
ments. Data collection instruments and the study
timeline are summarised in Table 1. All instruments
used have been previously validated and we also pre-
tested them in the Northern Irish population prior to
use in the study.
Primary outcomes
The three main outcomes of interest are changes in
body composition, fatigue and quality of life.
Body Composition
Measures of body composition include percentage body
fat (assessed from skin fold thickness measured at 4
sites; triceps, biceps, subscapular and suprailiac using a
Harpenden Skinfold Calipers), height, (measured to the
nearest centimetre using SECA Leicester Height Mea-
sure), weight (SECA 704 Electronic Column Scale), body
mass index (BMI) (Kg/M2), waist and hip circumference
as a measure of central adiposity and mid upper arm
circumference as a measure of lean body mass. A stan-
dard protocol is used to conduct all anthropometric
measurements [20].
Fatigue
The Fatigue Severity Scale (FSS) is a self-reported scale
and has been used previously in prostate cancer patients
treated with ADT [21] and in patients with advanced
stage cancer of the prostate [22]. Patients are asked to
report their degree of agreement (on a seven-point
scale) with nine items related to fatigue. Therefore,
scores can range between 9 (indicating minimum fati-
gue) and 63 (indicating maximum fatigue). The validity
of this scale is supported by its good correlation with
both the EORTC Fatigue scale (Spearman Rank Correla-
tion Coefficient r = 0.83) and the bi-dimensional fatigue
scale (r = 0.62). A previous study of cancer related fati-
gue reported that 95% of an elderly control population
without cancer scored less than 42 on the FSS scale
[22]. Therefore, in this study ‘severe fatigue’ for cancer
patients was defined as a score of 42 or greater based
on the results of a study by Stone et al in prostate can-
cer patients treated with ADT [21].
Quality of life
The Functional Assessment of Cancer Therapy-Prostate
(FACT-P) is used to assess prostate cancer related qual-
ity of life [23]. The FACT-P is a 40-item self-reported
Table 1 Data collection instruments at different assessment points
Baseline 3-month follow-up 6-month follow-up
Anthropometry X X X
FSS X X X
FACT-P X X X
7-DPARQ X X X
6-min Walk Test X X X
PSS-10 X X X
7DD X X X
Fasting blood sample X X X
TTM X
Questionnaire for background information X
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questionnaire assessing a range of quality of life
domains: physical, social/family, emotional, and func-
tional well being. In addition, a 12-item prostate cancer
subscale (PSC) which is specific to the symptoms and
side effects associated with prostate cancer treatment
such as body image, pain, urinary and sexual functioning
is also used. Responses to questions use a five-point
Likert-type scale ranging from 0 (not at all) to 4 (very
much). The scores are summed to produce a subscale
score for each domain assessed. The subscale scores
range from 0 to 28 for the physical, social/family, and
functional well being scales, 0 to 24 for the emotional
well being scale, and 0 to 48 for the PSC, and higher
scores represent better quality of life. The scores of
these four domains are summed to calculate the FACT-
G (Functional Assessment of Cancer Therapy-General)
and total scores of FACT-G and PSC are added up to
produce a FACT-P score. An additional score, the Trial
Outcome Index (TOI) is created by summing the physi-
cal well-being, functional well-being and PCS scores.
This instrument has been used previously in prostate
cancer patients receiving ADT [24]. It has been consid-
ered a reliable instrument with sensitivity to change in
prostate specific antigen (PSA) scores and performance
status [23].
Secondary outcomes
Secondary outcomes include nutrient intake, physical
activity and perceived stress.
Nutrient intake
To reduce the possibility of memory recall problems for
this older patient group a 7-day food diary (7DD) is
used to assess food and nutrient intake. The patients are
asked to record, in as much detail as possible, all food
and beverages consumed over a 7-day period. The food
diary contains instructions for completion, one page to
record foods and drinks eaten during seven time points
(before breakfast, breakfast, before lunch, lunch, before
dinner, dinner, after dinner) and alcohol over a 7 day
period. The instructions included the provision of typi-
cal portion sizes to help the patients to indicate the
amount of each food consumed. Patients are also
encouraged to describe the portion size consumed using
other measures if they wish, such as weight in grams or
ounces, or in household units, such as tablespoons,
cups, slices etc. At the time of the patients’ visit the
trained nutritionist clarified any omissions and collected
additional information if required such as the cooking
methods used, brands of foods consumed and portion
sizes if these were unclear. The 7DD has been used in
the UK EPIC (European Prospective Investigation of
Cancer and Nutrition) study [25] amongst others and is
a manageable method for our population. It has been
demonstrated that a 7DD provides a better estimate of
average intake than a food frequency questionnaire or a
24 hour-recall [25,26]. A computer based software pro-
gramme (WISP) will be used to interpret the food intake
data to provide nutrient and food group intake esti-
mates. The total number of servings of fruit and vegeta-
ble consumed will be calculated using the Food
Standard Agency guidelines [19].
A fasting blood sample is collected for analysis of
serum ferritin, antioxidant vitamins, dietary lipids (total
cholesterol, high-density lipoprotein, low-density lipo-
protein, triglycerides), C-reactive protein and albumin. A
total of 30 ml of blood is collected and following appro-
priate processing for serum and plasma are stored in
-80°C freezer.
Physical activity
Physical activity is assessed with 7-Day Physical Activity
Recall (7-DPARQ) [27,28]. This is an interviewer-admi-
nistered measure assessing current and recent past phy-
sical activity from the last 7 days. Information on
moderate, hard and very hard activities and time spent
sleeping is gathered from the interview and light activ-
ities is imputed from the time remaining. Additionally,
patients report how typical the week’s activity is com-
pared to their activity in the previous three months. The
7-DPARQ measures energy expenditure and yields a
summery score in kcal/kg-1/day-1 for the previous week.
It has been validated and used for prostate cancer
patients in previous studies [12,29].
Functional capacity is measured using a 6-min Walk
Test [30,31], which was used in previous studies of pros-
tate cancer patients [9,29]. This test includes a measure
of the distance walked, to the nearest metre in 6 min-
utes. This functional measure was chosen rather than a
measure of physiological fitness as it appears to be a
more suitable outcome for an elderly population [29].
The 6-min walk test has a high test-retest reliability
over a 2-week time frame (r = 0.87) [32].
Stress
Psychological stress is assessed using the Perceived
Stress Scale (PSS-10), which is the most widely used
psychological instrument for measuring the perception
of stress among prostate cancer survivors [33-35]. The
PSS-10 is a 10-item questionnaire designed to measure
the perceived stress and the degree to which patients
found their lives unpredictable, uncontrollable, or over-
loaded in last 1 month. Questions are rated on a
4-point Likert scale with responses ranging from 0 =
“never” to 4 = “very often.” [36]
Other assessments
The transtheoretical model (TTM) is used to assess a
patients’ readiness to change their lifestyle behaviour
[37]. Patients will be categorised according to their stage
of readiness to change and this information will
be taken into consideration in the analysis and
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interpretation of the impact of the intervention. Patients
are asked, ‘on average do you - eat at least 5 servings of
vegetables and fruits each day; avoid eating too much
fat; walk 30 minutes every day at a brisk pace, 3 to 5
times/week?’. Responses include: Yes - ‘more than six
months’ (interpreted as maintenance), ‘less than six
months’ (interpreted as action); No - ‘intend to in the
next 30 days’ (interpreted as preparation), ‘intend to in
the next 6 months’ (interpreted as contemplation) and
not intending to in the next 6 months (interpreted as
pre-contemplation). Stage of readiness to change is also
considered in the delivery of the intervention. For exam-
ple, the potential benefit of a dietary and physical activ-
ity intervention is really emphasised to those men who
are in a stage of contemplation/precontemplation with
respect to making diet and physical activity changes.
A structured questionnaire is used to collect informa-
tion on age, socioeconomic status, education, family and
social support, tobacco and alcohol intake, barriers to
exercise and diet, supplementation use and family his-
tory of prostate cancer. A clinical history, including the
date of diagnosis, stage of disease and treatment details
is recorded from the patient’s medical notes during
screening. Data related to adverse events are collected
continuously via follow-up phone call.
Quality control
Following the initial visit, patients are contacted by
phone every 2 weeks for the first 3 months and every
3 weeks thereafter to monitor progress and compliance
with the intervention and to record any possible adverse
events. The control group is also contacted every
6 weeks, for a general discussion about their condition.
To standardise the follow-up call a written check-list
has been used and relevant information (walking steps
from the previous week and their goal for the current
week, illness etc.) are collected. Each participant is
encouraged to bring their partner or care-giver on the
day of data collection and to be present for the nutri-
tionist’s visit at their home to help to answer questions
regarding dietary intake and food preparation for those
who may not be actively involved in food shopping and
cooking. It is also hoped that by involving the patient’s
partner/care-giver, the patient is encouraged to comply
with the intervention at home. The baseline and follow-
up (3 month and 6 month) body composition measure-
ments are completed by the same person to avoid inter-
interviewer bias. However, this person is not masked to
treatment assignment. Although it is preferable to have
any subjective measurements, such as body composition
measurements, taken by a person who is masked to
treatment allocation, this was not possible in the present
study and in order to minimise any bias that may be
introduced, all body measurements are taken and
recorded without referring to the previously recorded
measurements.
Compliance and drop-outs
Compliance is monitored through follow-up telephone
calls and will be reported. Adherence to the intervention
is examined at the patient’s 3 month visit and an addi-
tional session with the nutritionist is arranged if neces-
sary to provide additional dietary advice, recalculation of
energy requirements and for encouragement. This also
provides an opportunity to address any problems or dif-
ficulties being encountered by the patient, and to pro-
vide feedback. The number of patients that drop-out
and their reasons for doing so will be documented but
following the intent to treat analysis they will be
included in data analysis until the point of drop-out.
Differences in dropout rates and the reason for drop out
will be assessed by group (intervention versus control).
Data storage and confidentiality
All questionnaires are stored in a locked cabinet in a
locked room, and have a unique identification number.
Consent forms are stored separately from study ques-
tionnaires in a locked cabinet. Only anonymised data is
entered into the computerised study database, and
access to the database is restricted to the study team.
Data will be stored for 17 years according to rules of
the Belfast Health and Social Care Trust.
Statistics
The data collected in the trial will be analysed based on
intention to treat and lost to follow-up cases will be
considered as missing observations [38]. Change over
the treatment period will be calculated by subtracting
the baseline value from the value at month 3 and
month 6. Primary and secondary endpoints between
those assigned to the intervention and control group
will be compared using analysis of covariance
(ANCOVA) with baseline scores included in the models
as covariates. Skewed data will be log transformed prior
to inclusion in the ANCOVA models. The trial outline
conforms to the Consort statement guidelines.
Ethical considerations
The study protocol has been approved by the Office for
Research Ethics Committees Northern Ireland
(ORECNI), the Research Governance of Belfast Health
and Social Care Trust and Queen’s University Belfast.
Permission to contact patients is received from the con-
sultants of the Northern Ireland Cancer Centre before
approaching the patients. Informed written consent is
collected from each participant. A telephone number
and contact address is provided to patients for any
queries they may have during the study period.
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Discussion
As far as we are aware, this is the first RCT to assess
whether a combined diet and physical activity interven-
tion can attenuate the negative changes in body compo-
sition associated with use of ADT in prostate cancer
patients and also to assess its impact on fatigue and
quality of life. The intervention period in the present
study is longer than previous studies (12-20 weeks of
physical activity interventions [8-11]) and, in keeping
with current views that initiation and maintenance of a
diet and physical activity modification for cancer survi-
vors should be tailored to the survivor’s condition and
personal preferences [16], it is individually tailored to
the patient. Moreover, patients’ readiness to change life-
style behaviours using the transtheoretical model is con-
sidered during the delivery of the intervention. This
model has been used successfully in previous diet and
exercise intervention studies [12,13,39]. We expect that
by using these approaches we will increase compliance
and achieve the greatest possible change in behaviour
and in the outcomes of interest. The intervention is also
home rather than hospital based and is therefore more
likely to be sustained in this older population group
[13,14,40,41]. Moreover, the study sample size is suffi-
cient to detect a clinically relevant change in body com-
position and the study includes a range of validated
physiological and psychological assessments, which will
maximise the internal validity of the study.
The majority of ADT treated prostate cancer patients
are overweight and obese [42]. Though we are not pro-
moting a weight reducing diet, and weight reduction is
not the primary goal of the intervention, it is likely that
an improvement in dietary intake and a higher level of
physical activity will result in modest weight loss in the
intervention group. It is known that overweight and
obesity is associated with an increased risk of chronic
diseases including cardiovascular disease, diabetes, some
forms of cancer and recurrence of cancer. Therefore,
maintenance of weight or gradual weight loss in the
intervention group can be viewed as a favourable out-
come [43]. Because our intervention incorporates both
dietary modification and physical activity, we will not be
able to separate out the effects specifically attributable
to either of these components. Furthermore, with no
allocation concealment the control group patients will
be free to change their diet and increase their physical
activity; even though such behaviour may weaken any
observed associations in the intervention arm.
The external validity of the study will depend on the
representative of the patient population from which we
recruit and on the proportion of eligible patients who
agree to participate in the study. For logistic reasons,
recruitment is limited to one centre, which is the
regional oncology centre (in Belfast) and patients treated
within this centre may not be representative of all pros-
tate cancer patients treated with ADT. Also, the charac-
teristics of recruited patients may be influenced by the
study design e.g. patients who agree to take part in the
trial may be more likely to be older or retired or highly
motivated, as involvement in the study demands three
additional clinic visits for outcome measurement.
Patients living outside of the Belfast area may be more
likely to decline in order to avoid more frequent jour-
neys to the clinic and the associated additional costs
that may be incurred. However, we are making every
effort to arrange our follow-up visits to coincide with
the patients’ 3-monthly follow-up visits with their con-
sultants to minimise travel. A positive aspect of our
approach to recruitment is that potential participants
have to be initially approached by their consultant
which may lead to a better uptake than other
approaches to recruitment e.g. community advertise-
ment [44].
Thus study will determine whether a healthy life style
intervention in prostate cancer patients can attenuate
the adverse body composition changes associated with
ADT. If successful, this intervention may lead to sub-
stantial and important changes in the management of
prostate cancer patients.
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